论文部分内容阅读
目的:观察草分枝杆菌F·U·36治疗儿童支气管哮喘的疗效及其对机体免疫的影响。方法:哮喘病儿38例,分为治疗组20例,对照组18例。2组急性发作期均给吸入肾上腺素β2受体激动剂(特布他林500μg,tid)及糖皮质激素(布地奈得200μg,bid或tid)。治疗组在此基础治疗上加用草分枝杆菌F·U·36疫苗1.72μg,im,每周1次,共10wk。结果:治疗组治疗前后FEV1,PEF,CD3,CD4,CD8,IL4,IFNγ差值分别为(445±s260)mL,(1.1±0.6)L·s-1,(1.7±1.1)%,(3.1±1.5)%,(2.0±1.3)%,(18±10)mg·L-1,(85±47)mg·L-1(均P<0.01);对照组治疗前后以上各指标差值分别为(210±202)mL,(0.6±0.4)L·s-1,(0.7±1.2)%,(1.1±1.2)%,(0.6±1.1)%,(7±10)mg·L-1,(25±31)mg·L-1(P<0.01和P<0.05)。2组组间比较亦有显著差异或非常显著差异(P<0.05或P<0.01)。但治疗夜间发作次数,吸入特布他林日数分别为治疗组(1.1±0.8)次·wk-1,(1.8±1.8)d;对照组(1.1±0.4)次·wk-1,(1.2±1.8)d,差异无显著意义(P均>0.05)。结论:草分枝杆菌F·U·36治疗儿童支气管哮喘疗效显著,能有效地改善免疫学功能。
Objective: To observe the curative effect of Mycobacterium phlei F · U · 36 on children with bronchial asthma and its effect on immune system. Methods: Thirty-eight children with asthma were divided into treatment group (20 cases) and control group (18 cases). Adiponectin β2 agonist (terbutaline 500 μg, tid) and glucocorticoid (budesonide 200 μg, bid or tid) were given to both groups during the acute episode. The treatment group in this basic treatment plus Mycobacterium phlei F · U · 36 vaccine 1.72μg, im, once a week for a total of 10wk. Results: The differences of FEV1, PEF, CD3, CD4, CD8, IL4 and IFNγ before and after treatment in the treatment group were (445 ± s260) mL, 1.1 ± 0.6 and 1.7 ± 1.1% ± 1.5%, 2.0 ± 1.3%, 18 ± 10 mg · L-1 and 85 ± 47 mg · L-1, respectively (all P <0.01) (0.7 ± 1.2)%, (1.1 ± 1.2)%, (0.6 ± 1.1)%, (7 ± 10) mg · L -1 , (25 ± 31) mg · L -1 (P <0.01 and P <0.05). There was also significant or very significant difference between the two groups (P <0.05 or P <0.01). However, the number of seizures at night and the number of terbutaline inhalation were (1.1 ± 0.8) times wk-1, (1.8 ± 1.8) days in treatment group, 1.1 ± 0.4 times wk-1 in control group (1.2 ± 1.8) d, no significant difference (P> 0.05). Conclusion: Mycobacterium phlei F · U · 36 is effective in treating bronchial asthma in children and can effectively improve the immunological function.